ank was subtracted from each 
reading. Superoxide anion production was expressed as the percentage increase from baseline values. Protein concentrations were determined with protein assay reagent. Protein analysis by Western blot Proteins were extracted from aorta and VSMC in culture, separated by electrophoresis on a 10% polyacrylamide gel, and transferred onto a nitrocellulose membrane, as previously described. Nonspecific binding sites were blocked with 5% skim milk in Tris-buffered saline solution with Tween for 1 h at 24uC. Membranes were then incubated with phospho-specific antibodies overnight at 4uC. Antibodies were incubated with anti-extracellular signal-regulated kinase . The ERK1/2 nonphosphoantibodies were also used in the present study. In other series of experiments membranes from VSMC were then incubated with anti-B1R . Antibodies were purchased from Santa Cruz Biotechnology or Cell Signaling Technology. Statistical analysis Data are means 6 SEM of n samples. B1R and AT1 mRNA levels were measured relative to b-actin mRNA levels. B1R and Angiotensin II and Kinin Vascular Interaction 4 Angiotensin II and Kinin Vascular Interaction PCNA protein levels were measured PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/19717526 relative to b-actin protein. pERK1/2 protein expression was normalized to total ERK1/2 levels. Statistical analysis was performed with GraphPad Prism software. Results were analyzed by one-way ANOVA in conjunction with a Bonferroni post-test for in vivo study or by one-way ANOVA followed by Dunnett’s test for multiple comparisons with control cells. P,0.05 was considered significant. Results ANG II increases B1R expression in aorta and in VSMC ANG II infusion increased aortic B1R mRNA expression in comparison with control. The B1R antagonist did not interfere with the effects of ANG II on B1R expression. Treatment with LOS inhibited ANG IIinduced increased aortic B1R mRNA expression. Neither ANG II, ANG II+DAL nor ANG PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/19717794 II+LOS infusion altered AT1 receptor mRNA vascular expression when compared to those in aortas of control rats. We also examined the effect of ANG II on B1R protein expression in aortic VSMC at different time points. As shown in with the control group, measured at the 7th and 14th days. Treatment with the B1R antagonist did not interfere with the increase in systolic arterial pressure observed in ANG II-infused rats. On the other hand, the AT1 receptor antagonist LOS blunted ANG II-induced hypertension. After 2-weeks of ANG II infusion the CSA and wall thickness were increased approximately 40% and 31%, respectively, when compared with control. B1R antagonism reduced and AT1 receptor antagonism prevented the ANG IIinduced changes in CSA and wall thickness. There were no differences in W/L ratio among the groups. B1R antagonism reduces vascular ROS generation and ERK1/2 phosphorylation in ANG II-infused rats Aortic sections from ANG II-infused rats exhibited increased ROS generation, demonstrated as enhancement of the red fluorescent dots when compared with control rat aortas. Treatment with the B1R antagonist reduced ROS generation in aortas from ANG II-infused rats. The HPLC analyses demonstrated a higher EOH/DHE concentration in aortas of the ANG II rats when compared with the control rats, and the B1R antagonist treatment corrected that. In contrast, no SB 203580 site alteration in E/DHE generation has been observed among the groups. ERK1/2 phosphorylation was increased in aortas from ANG II-infused rats when compared with control and ANG II+DAL rat aortas.Aorta
Posted inUncategorized